92822-01-0

Basic information

• Product Name: 4-(4-METHYL-BENZYL)-PIPERIDINE
• Synonyms: 4-(4-METHYL-BENZYL)-PIPERIDINE;4-[(4-methylphenyl)methyl]Piperidine
• CAS NO: 92822-01-0
• Molecular Formula: C₁₃H₁₉N
• Molecular Weight: 189.3
• Mol File: 92822-01-0.mol

Chemical Properties

• Boiling Point: 298.9°C at 760 mmHg
• Flash Point: 137.5°C
• Appearance: /
• Density: 0.96g/cm³
• Vapor Pressure: 0.00124mmHg at 25°C
• Refractive Index: 1.525
• PKA: 10.60±0.10(Predicted)
• CAS DataBase Reference: 4-(4-METHYL-BENZYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-METHYL-BENZYL)-PIPERIDINE(92822-01-0)
• EPA Substance Registry System: 4-(4-METHYL-BENZYL)-PIPERIDINE(92822-01-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 92822-01-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-METHYL-BENZYL)-PIPERIDINE is used as a building block for the synthesis of complex molecules, particularly in the development of new pharmaceuticals. Its structure and properties make it suitable for use as an intermediate in the production of a wide range of chemicals, including pharmaceuticals, agrochemicals, and specialty chemicals.
Used in Organic Synthesis:
4-(4-METHYL-BENZYL)-PIPERIDINE is used as a key intermediate in organic synthesis for the preparation of complex molecules. Its unique structure allows for the creation of various organic compounds, contributing to the advancement of chemical research and development.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(4-METHYL-BENZYL)-PIPERIDINE is utilized as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its role in the production of these chemicals helps to improve agricultural productivity and crop protection.
Used in Specialty Chemicals Production:
4-(4-METHYL-BENZYL)-PIPERIDINE is also employed in the production of specialty chemicals, which are high-value, custom-tailored compounds used in various industries such as cosmetics, fragrances, and coatings. Its versatility and unique properties make it an essential component in the synthesis of these specialized products.

InChI:InChI=1/C13H19N/c1-11-2-4-12(5-3-11)10-13-6-8-14-9-7-13/h2-5,13-14H,6-10H2,1H3

Upstream product

• 242487-87-2 1-benzyl-4-(4-methylbenzylidene)piperidine 
• 33974-28-6 α-(4-methylphenyl)-4-pyridinemethanol 
• 872-85-5 pyridine-4-carbaldehyde 
• 106-38-7 para-bromotoluene 
• 3762-25-2 diethyl 4-methylbenzylphosphonate 
• 104-82-5 4-Methylbenzyl chloride 

Downstream Products

• 496056-39-4 [4-(4-methyl-benzyl)-piperidin-1-yl]-oxo-acetic acid ethyl ester 
• 192990-02-6 4-(4-methylbenzyl)-1-but-3-ynylpiperidine 
• 496056-40-7 [4-(4-methyl-benzyl)-piperidin-1-yl]-oxo-acetic acid 
• 338466-88-9 2-{3-[4-(4-methyl-benzyl)-piperidin-1-yl]-propyl}-1H-benzimidazole 
• 193356-65-9 4-(-4-Methylbenzyl)-1-(2-(4-methylaminophenoxy)ethyl)piperidine 
• 193356-84-2 4-(4-Methylbenzyl)-1-(2-(2-hydroxynaphth-6-oxy)ethyl)piperidine 

Relevant articles and documents

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS

2-[(4-Benzyl)-1-piperidinyl)-methyl]benzimidazole-5-ol derivatives are NMDA NR2B receptor antagonists useful in the treatment of pain and other NMDA mediated diseases.

NR2B-Selective N-Methyl-D-aspartate Antagonists: Synthesis and Evaluation of 5-Substituted Benzimidazoles

Two classes of 5-substituted benzimidazoles were identified as potent antagonists of the NR2B subtype of the N-methyl-D-aspartate (NMDA) receptor. Selected compounds show very good selectivity versus the NR2A, NR2C, and NR2D subtypes of the NMDA receptor as well as versus hERG-channel activity and α1-adrenergic binding. Benzimidazole 37a shows excellent activity in the carrageenan-induced mechanical hyperalgesia assay in rats as well as good pharmacokinetic behavior in dogs.

Subtype-selective N-methyl-D-aspartate receptor antagonists: Synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines

A search of our compound library for compounds with structural similarity to ifenprodil (5) and haloperidol (7) followed by in vitro screening revealed that 4-benzyl-1-(4-phenyl-3-butynyl)piperidine (8) was a moderately potent and selective antagonist of the NR1A/2B subtype of NMDA receptors. Substitution on the benzyl group of 8 did not significantly affect NR1A/2B potency, while addition of hydrogen bond donors in the para position of the phenyl group enhanced NR1A/2B potency. Addition of a hydroxyl moiety to the 4-position of the piperidine group slightly reduced NR1A/2B potency while reducing α-1 adrenergic and dopamine D2 receptor binding affinities substantially, resulting in improved overall selectivity for NR1A/2B receptors. Finally, the butynyl linker was replaced with propynyl or pentynyl. When the phenyl was para substituted with amine or acetamide groups, the NR1A/2B potency order was butynyl > pentynyl >> propynyl. For the para methanesulfonamide or hydroxyl groups, the order was butynyl ? propynyl > pentynyl. The hydroxyl propyne (48) and butyne (23) were among the most potent NR1A/2B antagonists from this study. They both potentiated the effects of L-DOPA in the 6-hydroxydopamine-lesioned rat, a model of Parkinson's disease, dosed at 10 mg/kg ip, but 48 was not active at 30 mg/kg po.

Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives

Compounds of the formula: STR1 wherein R1 is hydrogen, halogen, trifluoromethyl, alkyl, hydroxyl, alkyoxy, benzyloxy, alkanoyloxy, or benzoyloxy, or when R2 is hydroxyl or methoxy in the 4-position and R3 is hydrogen, R1 may also represent hydroxymethyl carbamoyl or alkoxycarbonyl, R2 is hydrogen, halogen, alkyl, hydroxyl, or alkoxy, R3 is hydrogen or alkyl, R4 is alkyl (in which case the compounds are (±)-erythro) or when R3 represents hydrogen, R4 may also be hydrogen, and R5 is hydrogen, halogen, alkyl, alkoxy, or three methoxy groups in the 3-, 4- and 5-positions and pharmaceutically acceptable acid addition salts thereof, with the exclusion of compounds wherein: (a) one of R1 and R2 is in the 4-position and is hydroxyl, alkoxy or benzyloxy, the other is in the 3-position and is hydrogen, hydroxyl, alkoxy or benzyloxy, and R3 and R5 are hydrogen and wherein: (b) R1 is in the 4-position and is halogen, R4 is methyl and R2, R3 and R5 are hydrogen, are useful as medicaments.